Publication
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial
Journal Paper/Review - Jan 27, 2022
Geyer C E, Symmans W F, Rastogi P, Sohn J, Young R, Wright G S, Harkness C, McIntyre K, Yardley D, Dunbar M, Metzger O, Ponce Lorenzo J, Sikov W M, Huober Jens, Rugo H S, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Loibl S
Geyer, C E
1
0
Sikov, W M
1
0
Huober, Jens
chief physicianBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
297
12
Rugo, H S
1
0
Wolmark, N
1
0
O'Shaughnessy, J
1
0
Maag, D
1
0
Untch, M
19
0
Golshan, M
1
0
Ponce Lorenzo, J
1
0
Metzger, O
1
0
Dunbar, M
1
0
Symmans, W F
1
0
Rastogi, P
1
0
Sohn, J
1
0
Young, R
1
0
Wright, G S
1
0
Harkness, C
1
0
McIntyre, K
1
0
Yardley, D
1
0